GlaxoSmithKline is reviewing “all strategic options” for its Lucozade and Ribena brands as it continues to overhaul its European business.
The pharmaceuticals giant revealed the move as it released its full-year results. Pre-tax profits fell 4% to £7.6bn in the 12 months to 31 December 2012, on sales down 1% at £26.4bn.
The two drinks brands fall under GSK’s consumer healthcare business, which increased sales by 5% in 2012, boosted by growth in oral care and nutrition & wellness.
Lucozade Energy is the UK’s biggest sports and energy drink, with sales up 6.5% to £273m last year [Nielsen 52 weeks to 13 October 2012]. Ribena is the UK’s fourth biggest juice drink, with sales of £83.6m last year.
“We have decided to initiate a review evaluating all strategic options for the Lucozade and Ribena drinks brands, which are primarily marketed in established western markets,” confirmed CEO Sir Andrew Witty.
“These brands are iconic and the review will look at the best ways to ensure their continued growth,” he added.
No comments yet